Host Dr. Narjust Florez leads a discussion about the data from the KEYNOTE 671 trial, presented at ASCO 2023 and ESMO 2023, that led to the first approval of the combination of pembrolizumab plus chemotherapy in the neoadjuvant and adjuvant setting.

Podcast Hosts:

• Narjust Florez, MD, Associate Director of the Cancer Care Equity Program and Thoracic Medical Oncologist, Dana-Farber Cancer Institute; Assistant Professor of Medicine, Harvard Medical School, USA  

Podcast Guests: 

• Coral Olazagasti, MD, Assistant Professor, Sylvester Cancer Center, University of Miami, USA
• Jonathan Spice, MD, PhD, FRCS, Division of Thoracic Surgery Director, MdGill University, Canada